Developments in psoriasis and psoriatic arthritis

Drug Discovery Today: Disease Mechanisms

Volumn 5, Issue 1, 2008, Pages

  Feletar, Marie ^a   Foley, Peter ^b   Brown, Matthew A ^c,d  

^a Saint Vincents Hospital Melbourne ^*

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; CALCIPOTRIOL; CYCLOSPORIN; DIHYDROFOLATE REDUCTASE; DIHYDROOROTATE DEHYDROGENASE; EFALIZUMAB; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; ETRETIN; ETRETINATE; GOLIMUMAB; HLA ANTIGEN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 15; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; LEFLUNOMIDE; METHOTREXATE; PLACEBO; RITUXIMAB; ROSIGLITAZONE; TAZAROTENE; USTEKINUMAB; VITAMIN D;

ADAPTIVE IMMUNITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOPATHOLOGY; INHIBITION KINETICS; INNATE IMMUNITY; KERATINOCYTE; MEDICAL DECISION MAKING; PATHOGENESIS; PHOTOTHERAPY; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 67349139415     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2008.05.001     Document Type: Review

References (92)

1. Glickman F.S. Lepra, psora, psoriasis. J. Am. Acad. Dermatol. 14 5 Pt 1 (1986) 863-866
2. Griffiths C.E., and Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 370 (2007) 263-271
3. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin. Exp. Dermatol. 26 (2001) 314-320
4. Krueger G., and Ellis C.N. Psoriasis - recent advances in understanding its pathogenesis and treatment. J. Am. Acad. Dermatol. 53 1 Suppl. 1 (2005) S94-S100
5. Bowcock A.M., and Krueger J.G. Getting under the skin: the immunogenetics of psoriasis. Nat. Rev. Immunol. 5 (2005) 699-711
6. Nickoloff B.J., and Nestle F.O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113 (2004) 1664-1675
7. Valdimarsson H., et al. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?. Immunol. Today 16 (1995) 145-149
8. Austin L.M., et al. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113 (1999) 752-759
9. Robert C., and Kupper T.S. Inflammatory skin diseases, T cells, and immune surveillance. N. Engl. J. Med. 341 (1999) 1817-1828
10. Smith C.H., and Barker J.N. Psoriasis and its management. BMJ 333 (2006) 380-384
11. Lowes M.A., et al. Pathogenesis and therapy of psoriasis. Nature 445 (2007) 866-873
12. Vissers W.H., et al. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br. J. Dermatol. 150 (2004) 852-859
13. Davison S.C., et al. Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques. Exp. Dermatol. 10 (2001) 280-285
14. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46 (2002) 1-23 quiz 23-6
15. Gaspari A.A. Innate and adaptive immunity and the pathophysiology of psoriasis. J. Am. Acad. Dermatol. 54 3 Suppl. 2 (2006) S67-S80
16. Nickoloff B.J. Skin innate immune system in psoriasis: friend or foe?. J. Clin. Invest. 104 (1999) 1161-1164
17. Nestle F.O., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. 202 (2005) 135-143
18. Gaspari A.A. Mechanism of action and other potential roles of an immune response modifier. Cutis 79 4 Suppl. (2007) 36-45
19. Gilliet M., et al. Psoriasis triggered by Toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch. Dermatol. 140 (2004) 1490-1495
20. Fanti P.A., et al. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int. J. Dermatol. 45 (2006) 1464-1465
21. Wilson N.J., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8 (2007) 950-957
22. Takahashi H., et al. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J. Dermatol. Sci. 31 (2003) 21-28
23. Halsall J.A., et al. Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. Pharmacogenet. Genomics 15 (2005) 349-355
24. Beissert S., and Schwarz T. Role of immunomodulation in diseases responsive to phototherapy. Methods 28 (2002) 138-144
25. Menter A., and Griffiths C.E. Current and future management of psoriasis. Lancet 370 (2007) 272-284
26. Mueller W., and Herrmann B. Cyclosporin A for psoriasis. N. Engl. J. Med. 301 (1979) 555
27. Santini M.P., et al. Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9575-9580
28. Pershadsingh H.A., et al. Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. Skinmed 4 (2005) 386-390
29. Mohanty P., et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 89 (2004) 2728-2735
30. Ellis C.N., et al. Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone. Am. J. Clin. Dermatol. 8 (2007) 93-102
31. Nash P., et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 212 (2006) 238-249
32. Gladman D.D. Natural history of psoriatic arthritis. Baillieres Clin. Rheumatol. 8 (1994) 379-394
33. Salvarani C., et al. Prevalence of psoriatic arthritis in Italian psoriatic patients. J. Rheumatol. 22 (1995) 1499-1503
34. Green L. Arthritis in psoriasis. Ann. Rheum. Dis. 40 (1981) 366-369
35. Moll J.M., and Wright V. Psoriatic arthritis. Semin. Arthritis Rheum. 3 (1973) 55-78
36. Taylor W., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 54 (2006) 2665-2673
37. Chandran V., et al. CASPAR criteria are sensitive in early psoriatic arthritis. Arthritis Rheum. Suppl. 1 (2006)
38. Soriano E.R., and McHugh N.J. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J. Rheumatol. 33 (2006) 1422-1430
39. Kaltwasser J.P., et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 50 (2004) 1939-1950
40. Wakefield P.E., et al. Tumor necrosis factor. J. Am. Acad. Dermatol. 24 5 Pt 1 (1991) 675-685
41. Mease P.J., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 50 (2004) 2264-2272
42. Antoni C.E., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52 (2005) 1227-1236
43. Antoni C., et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 64 (2005) 1150-1157
44. Kavanaugh A., et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann. Rheum. Dis. 65 (2006) 1038-1043
45. van der Heijde D., et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 56 (2007) 2698-2707
46. Mease P.J., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52 (2005) 3279-3289
47. Gladman D.D. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 56 (2007) 476-488
48. Knight D.M., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30 (1993) 1443-1453
49. Scallon B.J., et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7 (1995) 251-259
50. Menter A., et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J. Am. Acad. Dermatol. 56 (2007) 31 e1-e15
51. Papoutsaki M., et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J. Am. Acad. Dermatol. 57 (2007) 269-275
52. Kavanaugh A., et al. Golimumab, a new, human, TNF-alpha Antibody administered as a monthly subcutaneous injection in psoriatic arthritis: 24-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. Arthritis Rheum. 56 Suppl. 1 (2007) 1
53. Beuthien W., et al. Skin reaction to adalimumab. Arthritis Rheum. 50 (2004) 1690-1692
54. Grinblat B., and Scheinberg M. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. Arthritis Rheum. 52 (2005) 1333-1334 author reply 1334
55. Grinblat B., and Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin. Arthritis Rheum. 37 4 (2008) 251-255
56. Gottlieb A., et al. Phase II, randomized, placebo-controlled study of CNTO 1275, a human interleukin-12/23 monoclonal antibody, in psoriatic arthritis. Arthritis Rheum. 56 Suppl. 1 (2007)
57. Wallner B.P., et al. Primary structure of lymphocyte function-associated antigen 3 (LFA-3). The ligand of the T lymphocyte CD2 glycoprotein. J. Exp. Med. 166 (1987) 923-932
58. Majeau G.R., et al. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J. Immunol. 152 (1994) 2753-2767
59. Chamian F., et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in Psoriasis vulgaris. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2075-2080
60. Ellis C.N., and Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345 (2001) 248-255
61. Mease P.J., et al. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 54 (2006) 1638-1645
62. Krueger J., et al. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J. Invest. Dermatol. 115 (2000) 333
63. Lebwohl M., et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349 (2003) 2004-2013
64. Papp K.A., et al. Efalizumab for the treatment of psoriatic arthritis. J. Cutan. Med. Surg. 11 (2007) 57-66
65. Myers W.A., et al. New-onset, debilitating arthritis in psoriasis patients receiving efalizumab. J. Dermatol. Treat. 17 (2006) 353-354
66. Bang B., and Gniadecki R. Severe exacerbation of psoriatic arthritis during treatment with efalizumab. A case report. Acta Derm. Venereol. 86 (2006) 456-457
67. Gladman D.D., et al. Outcome measures in psoriatic arthritis. J. Rheumatol. 34 (2007) 1159-1166
68. Mease P.J., et al. Psoriatic arthritis assessment tools in clinical trials. Ann. Rheum. Dis. 64 Suppl. 2 (2005) ii49-ii54
69. Moll J.M., and Wright V. Familial occurrence of psoriatic arthritis. Ann. Rheum. Dis. 32 (1973) 181-201
70. Nash P., et al. Seronegative spondyloarthropathies: to lump or split?. Ann. Rheum. Dis. 64 Suppl. 2 (2005) ii9-ii13
71. Jenisch S., et al. Linkage analysis of human leukocyte antigen (HLA) markers in familial psoriasis: strong disequilibrium effects provide evidence for a major determinant in the HLA-B/-C region. Am. J. Hum. Genet. 63 (1998) 191-199
72. Degli-Esposti M.A., et al. Ancestral haplotypes: conserved population MHC haplotypes. Hum. Immunol. 34 (1992) 242-252
73. Tsunemi Y., et al. Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and Psoriasis vulgaris. J. Dermatol. Sci. 30 (2002) 161-166
74. Cargill M., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80 (2007) 273-290
75. Ziolkowska M., et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol. 164 (2000) 2832-2838
76. Duerr R.H., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006) 1461-1463
77. Burton P.R., et al. Association scan of 14 500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 39 (2007) 1329-1337
78. Krueger G.G., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356 (2007) 580-592
79. Consortium WTC-C. Genome-wide association study of 14 000 cases of seven common diseases and 3000 shared controls. Nature 447 (2007) 661-678
80. Steinthorsdottir V., et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat. Genet. 39 (2007) 770-775
81. Zeggini E., et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316 (2007) 1336-1341
82. Helms C., et al. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat. Genet. 35 (2003) 349-356
83. Huffmeier U., et al. Systematic linkage disequilibrium analysis of SLC12A8 at PSORS5 confirms a role in susceptibility to Psoriasis vulgaris. J. Invest. Dermatol. 125 (2005) 906-912
84. Hewett D., et al. Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics 79 (2002) 305-314
85. Butt C., Sun S., Greenwood C., Gladman D., and Rahman P. Lack of association of SLC22A4, SLC22A5, SLC9A3R1 and RUNX1 variants in psoriatic arthritis. Rheumatology (Oxford) 44 (2005) 820-821
86. Rahman P., et al. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am. J. Hum. Genet. 73 (2003) 677-681
87. Ho P., et al. Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum. 52 (2005) 3596-3602
88. Jenisch S., et al. CARD15 mutations in patients with plaque-type psoriasis and psoriatic arthritis: lack of association. Arch. Dermatol. Res. 297 (2006) 409-411
89. Plant D., et al. CARD15/NOD2 single nucleotide polymorphisms do not confer susceptibility to type I psoriasis. Br. J. Dermatol. 151 (2004) 675-678
90. Giardina E., et al. Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population. J. Invest. Dermatol. 122 (2004) 1106-1107
91. Young C., et al. A Crohn's disease-associated insertion polymorphism (3020insC) in the NOD2 gene is not associated with Psoriasis vulgaris, palmo-plantar pustular psoriasis or guttate psoriasis. Exp. Dermatol. 12 (2003) 506-509
92. Nair R.P., et al. Lack of association between NOD2 3020InsC frameshift mutation and psoriasis. J. Invest. Dermatol. 117 (2001) 1671-1672